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Abstract
Background: Acute hepatitis C virus (HCV) infection (AHCVI) outbreaks have been described recently within
defined areas worldwide among HIV-infected homosexual men. This study aims to describe the cumulative
frequency and incidence of firstly acquired AHCVI in an HIV-infected population in Southern Spain.
Methods: This is a retrospective study conducted at the Infectious Diseases Units of eight hospitals in Andalusia,
Southern Spain. Primary AHC was considered as HCV immunoglobulin G antibody seroconversion. The time of
infection was considered the moment between the last negative and the first positive HCV antibody determination.
Results: A total of 23 cases of primary AHCVI have been detected from 2000 to 2014. Incidence rates [IR; 95 %
confidence interval (CI)] were 0.036 (2.272–0.054) per 100 person-years (py) in the overall population over a
follow-up period of 64170 py. Of the 22 (95.7 %) male subjects, 21 (95.5 %) had acquired AHCVI by homosexual
contact, the IR (95 % CI) was 0.039 (0.024–0.06) per 100 py in this subpopulation. There was no evidence of an
increase of AHCVI IR. The incidence of AHCVI was slightly lower between 2000 and 2004 as compared to 2005–2009
[IR ratio (IRR) of 8.8 (95 % CI: 1.279–378.794; p = 0.01)] but reached a plateau afterwards [IRR between 2010 and 2014
versus 2005–2009: 0.727 (0.286–1.848; p = 0.5)]. The median (Q1-Q3) time between the last negative anti-HCV and the
first positive anti-HCV determination was 4.7 (1.9–11.2) months. Peak (Q1-Q3) ALT and total bilirubin values during
AHCVI were 496 (291–656) IU/mL and 1.15 (0.9–1.98) mg/dL, respectively.
Conclusions: In contrast to what has been reported from other areas, the incidence of primary AHCVI in the HIV-
infected population is stable in Southern Spain and there is no evidence of an epidemic, in spite of the high
prevalence of HIV/HCV-coinfection in this area.
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Background
In the last decade, various outbreaks of acute hepatitis C
virus infection (AHCVI) have been described among
HIV-infected individuals worldwide [1–10]. These epi-
demics have affected mainly men who have sex with
men (MSM) and have led to an increase in the incidence
of hepatitis C virus (HCV) infection in some particular
areas [5, 6]. Additionally, recent studies conducted in
very specific areas within large Spanish cities have re-
ported an increase in the number of cases of AHCVI
among HIV-infected MSM [7, 8].
To date, no cases of AHCVI among the HIV-infected
population from Southern Spain have been published, in
spite of the fact that in this area over one third of HIV-
infected subjects currently bear an active HCV coinfec-
tion [11]. This might suggest that, whatever the reason,
the occurrence of acute HCV infection outbreaks among
HIV-infected MSM is subject to regional variations.
However, cases of acute HCV infection may also go un-
noticed, since many of them are subclinical. Because of
this, underreporting of AHCVI could have underlied
the lack of detection of outbreaks of this disorder in
our area. It is to note that approximately 40 % of the
HIV-coinfected population in the Southern Spanish re-
gion of Andalusia does not show positive serology for
HCV and is thus susceptible for AHCVI. To provide
insight on this point, this study aimed to determine the
number of cases of firstly acquired AHCVI infection
among HIV-infected patients seen at eight Southern
Spanish hospitals, who attend a vast population of HIV-




This retrospective study was conducted in the Infec-
tious Diseases Units of eight hospitals throughout the
Southern Spanish provinces of Almeria, Cadiz, Huelva,
Malaga and Seville. All HIV-positive patients seen from
2000 to 2014 and who showed negative plasma IgG
antibody against HCV (anti-HCV) were included. In
our area, all HIV-infected patients are cared for at pub-
lic hospitals, where they attend at least once every
6 months, and may ask for additional visits when re-
quired or at their own decision. In all this institutions,
routine blood parameters, including liver function test
are conducted every visit. Also, HCV serum antibodies
are determined at the first visit and every 12–18 months,
as well as when clinically appropriated, in previously sero-
negative patients. All cases of firstly acquired AHCVI in
HIV-infected patients diagnosed in the above-stated insti-
tutions according to the below-stated criteria were ana-
lyzed retrospectively.
Definition of firstly acquired AHCVI
An episode of AHCVI was diagnosed in patients with
confirmed prior absence of anti-HCV if i) Anti-HCV
seroconversion or a 10-fold increase in ALT levels above
the upper limit of normality (ULN) along with detect-
able plasma HCV-RNA were observed; ii) Acute hepa-
titis B virus and hepatitis A virus infection were ruled
out by negative IgM anti-HBc and IgM anti-HAV tests
and iii) Toxic acute hepatitis was reasonably excluded.
The date of AHCVI was estimated as the midpoint be-
tween the date of the last anti-HCV negative result and
the date of the first positive determination or when
HCV-RNA was detected for the first time.
Laboratory determinations
Serological determinations were conducted by enzyme
immunoassay (ADVIA Centaur XP, Siemens Healthcare
Diagnostics S.L. Tarrytown, NY, USA or ELECSYS®
Anti-HCV II, Roche Diagnostics, Basel, Suisse). Plasma
HCV RNA was quantified as described elsewhere [12].
HCV genotype was determined using the VERSANT
HCV Genotype 2.0 kit (Siemens Healthcare, Erlangen,
Germany).
Statistical analysis
Descriptive statistics of demographic factors, HIV trans-
mission route and analytical values were carried out.
Incidence rates (IR) and the 95 % confidence intervals
(CI) of firstly acquired AHCVI were calculated and pre-
sented as cases per 100 person-years (py). Study periods
were defined as followed: 2000–2004 (period 1), 2005–
2009 (period 2) and 2010–2014 (period 3). Subsequently,
based on Poisson regression, IR ratios (IRR) were deter-
mined in order to evaluate the relative risk for acquisi-
tion of AHCVI between the different study periods, as
well as for possible geographic differences were calcu-
lated. Analyses were carried out by means of the SPSS
statistical software package release 23.0 (IBM Corpor-
ation, Somers, NY, USA) and STATA 9.0 (StataCorp LP,
College Station, TX, USA).
Ethical aspects
The study was designed and performed according to the
Helsinki declaration and was approved by the Ethics
Committee of the Valme University Hospital (Seville,
Spain). All patients gave their written informed consent.
Results
A total of 23 cases of primary AHCVI were detected. All
of them were observed in five of the eight participating
hospitals: 10 cases were reported from Malaga and the
remaining 13 individuals were identified in Seville. The
characteristics of the patients at the moment of AHCVI
diagnosis are listed in Table 1.
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No AHCVI episode was observed before 2004. The
majority (91.3 %) of the patients were MSM, none of
whom had any history of injecting drug use during
follow-up. The distribution of patients according to the
years of seroconversion is depicted in Fig. 1. Over a
follow-up period of 64170 py from 2000 to 2014, the
overall IR (95 % CI) was 0.036 (2.272–0.054) per 100 py.
The IR (95 % CI) for second and the first study period
were 0.054 (0.027–0.097) per 100 py versus 0.006
(0.001–0.034) per 100 py, resulting in an IRR of 8.8
(95 % CI: 1.279–378.794; p = 0.01). The IRR between the
third (IR 0.039 per 100 py; 95 % CI: 0.02–0.071) versus
the second period was 0.727 (0.286–1.848; p = 0.5). In
the subpopulation of MSM, the overall IR (95 %CI)
was 0.039 (0.024–0.06) per 100 py. The IR (95 % CI)
for the first, second and third study periods were 0.008
(0.001–0.041) per 100 py, 0.066 (0.032–0.121) per 100
py and 0.04 (0.19–0.073) per 100 py, respectively. The
corresponding IRR were 8.682 (95 % CI: 1.235–
376.792; p = 0.012) for the second versus the first
period and 0.605 (95 % CI: 0.226–1.62; p = 0.27) for
the third versus the second period. The IR for each
study year are shown in Fig. 1. A subanalysis to com-
pare the IR between Malaga and Seville revealed IR of
0.048 and 0.044, respectively (IRR: 0.937; 95 % CI:
0.38–2.388, p = 0.872). Figure 2 shows the number and
incidence of primary AHCVI per year.
The median (interquartile range, IQR) time between
the last negative anti-HCV and the first positive anti-
HCV determination was 4.7 (1.9–11.2) months. The me-
dian (IQR) peak ALT values and total bilirubin levels
during AHCVI were 496 (291–656) IU/mL and 1.15
(0.9–1.98) mg/dL, respectively. Fifteen (65.2 %) patients
showed 10-fold or greater increases in ALT levels above
the ULN throughout the episode of AHCVI. Likewise, 6
(26.1 %) individuals showed total bilirubin levels above
2 mg/dL at some point during acute infection.
Discussion
In this study, the number of firstly acquired AHCVI epi-
sodes among HIV-infected patients seen at 8 hospitals
from Southern Spain has not experienced a progressive
increase, as observed in other areas [3, 6–8]. Conversely,
Table 1 Characteristics of the patients at the moment of
diagnosis of acute HCV infection
Characteristic Value
Age (years)a 43.2 (34–46.1)
Male gender, n (%) 22 (95.7)
Race, n (%)
Caucasian 23 (100)
Risk factor for HCV acquisition, n (%)
Heterosexual contact 1 (4.3)
MSM 21 (91.3)
PWID 1 (4.3)
HCV genotype, n (%)
1 (1a/1b)b 19 (82.6) [10 (43,5)/ 2 (8,7)]
3 2 (8.7)
4 2 (8.7)
HCV RNA (log10 IU/mL)a 6.08 (5.37–6.98)
ALT (IU/mL)a 367 (234–614)
AST (IU/mL)a 181 (93–646)
Total bilirubin (mg/dL)a 1.1 (0.72–3.39)
MSM men who have sex with men, PWID people who inject drugs
aMedian (interquartile range); b7 subject did not have HCV genotype 1
subtype determination
Fig. 1 Number and incidence of patients rate with diagnosis of primary acute hepatitis C virus infection (AHCVI) among HIV-infected individuals
according to the years of infection. MSM: men who have sex with men
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the number of cases diagnosed after 2003 has remained
stable. This data strongly suggest that currently there is
no ongoing outbreak of AHCVI among HIV-infected pa-
tients in Southern Spain.
A recent analysis of a nationwide Spanish cohort of
HIV-infected individuals suggested an augmented HCV
follow-up testing of possible HCV seroconversion in the
HIV-infected population in the last years in our area
[13]. In spite of this, the incidence of AHCVI observed
in the present study did not change during the last years.
It is, however, to note that no cases of AHCVI were
reported between 2000 and 2003, which resulted in a
slightly lower IR for the first study period. Still, the in-
crease in the number of cases from before to after 2003
was minimum, with a peak of 4 patients per year.
Furthermore and in contrary to what was observed in
other cities, [1–10] the incidence of primary AHCVI has
been stable throughout the last decade, with no evidence
of a trend towards an increase.
Considerable increases of the number AHCVI epi-
sodes have been reported from very specific areas of
Spain. In this context, a retrospective study conducted
from 2008 to 2012 in an outpatient clinic of Madrid
reported 19 cases of AHCVI, seven of which were
diagnosed in 2012 [7]. Likewise, a case report derived
from a clinic attending the largest MSM community in
Madrid, reported four cases of recently acquired AHCVI
among MSM HIV-infected patients [9]. Additionally, a
retrospective analysis conducted in HIV-infected individ-
uals seen from 2003 to 2015 in a clinic from Barcelona,
which also attend a large community of MSM, reported
an important increase of AHCVI episodes. Thus, while
only 3 patients were diagnosed for AHCVI between
2003 and 2006, approximately one episode per month
was registered from 2007 to 2011, reaching a peak of
almost 30 diagnoses in 2012 [8]. Clearly, this tendency
is not observed in our study, despite the presence of a
MSM community especially in the costal area of
Southern Spain and in the Seville area [11]. Interest-
ingly, there was no also no difference in the incidences
of AHCVI when comparing the inland city of Seville
and the coastal city of Malaga.
The lack of an epidemic of AHCVI in an area where,
on the one hand, approximately 60 % of the HIV-
infected patients are positive for HCV antibodies [11]
and, on the other hand, only 20 % show active HCV-
infection, [14] is an intriguing point. This fact may have
different reasons. On the one hand, it has been specu-
lated that host genetic factors play a role in the suscepti-
bility of HCV infection [15]. However, the role of host
genetics in this context remains unclear and it is unlikely
that there is a significant genetic diversity between the
populations of Central/Northern Spain and the herein
analyzed individuals [16]. On the other hand, the results
of phylogenetic analyses of the viral strains and a dispro-
portionately high frequency of HCV genotype 4 infection
suggest a clustering of strains causing AHCVI outbreaks
in HIV-infected MSM [2, 4, 7, 17, 18]. Likewise, in HIV-
infected MSM with AHCVI in Spain, the proportion of
acute HCV genotype 4 infections is higher than expected
when compared to the prevalence of HCV genotype 4 in
chronically infected populations [7, 8]. Conversely, in
the present study acute infection with genotype 1 was
predominantly observed, standing in accordance with
the HCV genotype distribution commonly observed
among HIV/HCV-coinfected individuals seen in our area
[11]. Thus, this observation adds up to the conclusion
that the situation in Southern Spain is different to what
Fig. 2 Number and incidence of patients with diagnosis of primary acute hepatitis C virus infection (AHCVI) among HIV-infected individuals ac-
cording to the city where diagnoses took place
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is observed elsewhere. Finally, differences in sexual risk
behaviour may account for the lack of an epidemic in
our setting. While transmission of HCV is rare in HIV-
positive population, [6] and even more uncommon in
HIV-negative heterosexual couples, certain practices
often carried out by MSM, such as unprotected anal sex
with bleeding, fisting or group sex have been associated
with HCV transmission [3, 19, 20]. Additionally, in
MSM, HIV-coinfection itself might favour sexual HCV
transmission [21]. Although no comparative studies on
sexual risk behaviour have been conducted between dif-
ferent areas, data obtained from HIV-infected MSM in
our setting suggest that high risk behaviour is also com-
mon among them [22]. In our opinion, certain HCV
strains particularly infective through transmucosal way
may spread among a specific MSM subset with high risk
practises leading to an outbreak of AHCVI. It is unlikely
that this chain of events has taken place in our area so
far. This is supported by another Southern Spanish study
conducted in HIV-infected patients who had achieved
treatment-induced HCV clearance and which found a
very low incidence rate of reinfection with HCV [23].
However, this point requires further investigation but, if
confirmed, it would have important implications for pre-
venting HCV transmission among HIV-infected MSM.
The main limitation of this study is its retrospective
design. Indeed, since episodes of AHCVI are frequently
asymptomatic, [24] as in was the case in our patients,
we cannot rule out that some cases could have gone un-
noticed. However, it is unlikely that diagnosis of AHCVI
was missed to a great extent in our hospitals in the last
decade. In fact, HCV serology is usually performed at
the first visit and sequentially afterwards in order to
diagnose HCV infection at the Infectious Diseases Units
in our area. Still, a prospective study to evaluate the inci-
dence of AHCVI in HIV coinfection is warranted. This
study should include a detailed questionnaire about sexual
practices that enabled to compare data with those already
carried out in other regions.
Conclusions
In conclusion, the number of cases of primary AHCVI in
HIV-infected patients in Southern Spain is both low and
stable. Prospective studies to determine the incidence of
AHCVI, as well as the reasons for the lack of an epidemic
outbreak in this setting, are necessary. These data are
crucial for preventing AHCVI. In the meantime, aware-
ness and sequential screening for HCV antibodies in
seronegative patients are needed.
Abbreviations
AHCVI: Acute hepatitis C virus infection; anti-HCV: Plasma IgG antibody against
hepatitis C virus; HCV: Hepatitis C virus; IR: Incidence rate; IRR: Incidence rate
ratio; MSM: Men who have sex with men; ULN: Upper limit of normality
Funding
This work has been partially funded by the RD12/0017/0012 project as part
of the Plan Nacional R + D + I and cofinanced by ISCIII-Subdirección
General de Evaluación, the Fondo Europeo de Desarrollo Regional (FEDER),
and the Instituto de Salud Carlos III (grant number PI15/01124). K.N. is the
recipient of a Miguel Servet research grant from the Instituto de Salud Car-
los III (grant number CP13/00187). J.M. is the recipient of a grant from the
Servicio Andaluz de Salud de la Junta de Andalucía (grant number B-0037).
J.A.P. is recipient of an intensification grant from the Instituto de Salud Car-
los III (grant number Programa-I3SNS).
None of the funding body played a role in either study design, in the
collection, analysis, and interpretation of data, in the writing of the
manuscript or in the decision to submit the manuscript for publication.
Availability of data and materials
Raw data is available upon request from the corresponding author (Dr. Karin
Neukam, Unit of Infectious Diseases and Microbiology, Hospital Universitario
de Valme Avenida de Bellavista s/n, 41014 Seville, Spain; E-mail:
karin.neukam@gmail.com).
Authors’ contributions
Study design: KN, JAP. Data collection: PV, GOB, MDF, MJR, JM, DM, AC, FT.
Data analysis: KN, JAP. Manuscript preparation: KN, JMS, JAP. All authors read
and approved the final manuscript.
Competing interests
K.N. has received lecture fees from Janssen-Cilag, Roche, Bristol-Meyers
Squibb and Merck Sharp & Dohme and has received research support from
Janssen-Cilag, Bristol-Meyers Squibb, Merck Sharp & Dohme, Gilead Sciences
and Abbott Pharmaceuticals. J.M. has received lecture fees from Roche,
Gilead Sciences, Merck Sharp & Dome, Boehringer Ingelheim, Janssen-Cilag
and Bristol-Myers Squibb and consulting fees from Roche, Gilead Sciences,
Boehringer Ingelheim, Bristol Myers-Squibb and Merck Sharp & Dome. D.M.
reports having received consultancy fees from Janssen Cilag, Merck Sharp &
Dohme, Bristol-Myers Squibb, Gilead Sciences, AbbVie and ViiH Healthcare.
A.C. reports board membership of Janssen-Cilag, Merck Sharp & Dohme,
Bristol-Myers Squibb, Gilead Sciences and AbbVie. J.A.P. reports having
received consulting fees from GlaxoSmithKline, Bristol-Myers Squibb, Abbott
Pharmaceuticals, Gilead Sciences, Merck Sharp & Dohme, Schering-Plough,
Janssen-Cilag and Boehringer Ingelheim. He has received research support
from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott
Pharmaceuticals and Boehringer Ingelheim, and has received lecture fees
from GlaxoSmithKline, Roche, Abbott Pharmaceuticals, Bristol-Myers Squibb,
Gilead Sciences, Merck Sharp & Dohme, Janssen-Cilag, Boehringer Ingelheim
and Schering-Plough. All other authors: None to declare.
Consent for publication
Consent for publication does not apply.
Ethics approval and consent to participate
Both study design and conduct conformed to the Helsinki declaration
and was approved by the local Ethics Committees of the Valme University
Hospital (Comité de Ética de la Investigación Sevilla Sur, Seville, Spain; Ref.
02/2015). All patients gave their written informed consent to participate
in the study.
Author details
1Unit of Infectious Diseases and Microbiology, Hospital Universitario de
Valme, Avenida de Bellavista S/N, 41014 Seville, Spain. 2Instituto de
Biomedicina de Sevilla (IBiS), Avenida Manuel Siurot S/N, 41013 Seville, Spain.
3Infectious Diseases, Microbiology and Preventive Medicine, Hospital
Universitario Virgen del Rocío, Avenida Manuel Siurot S/N, 41013 Seville,
Spain. 4Unit of Infectious Diseases, Hospital Universitario Virgen de la Victoria,
Campus Universitario Teatinos, 29010 Malaga, Spain. 5Unit of Infectious
Diseases, Hospital Regional de Málaga, Avenida de Carlos Haya, S/N, 29010
Malaga, Spain. 6Unit of Infectious Diseases, Hospital Universitario Virgen de la
Macarena, Avenida Dr. Fedriani 3, 41007 Seville, Spain. 7Unit of Infectious
Diseases, Complejo Hospitalario de Huelva, Ronda Exterior Norte S/N, 21005
Huelva, Spain. 8Unit of Infectious Diseases, Hospital Torrecárdenas, Calle
Hermandad Donantes de Sangre S/N, 04009 Almeria, Spain. 9Unit of Infectious
Neukam et al. BMC Infectious Diseases  (2016) 16:489 Page 5 of 6
Diseases and Microbiology, Hospital La Línea, AGS Campo de Gibraltar, Avenida
Menéndez Pelayo 103, 11300 La Linea de la Concepcion, Spain.
Received: 9 March 2016 Accepted: 9 September 2016
References
1. Götz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de
Zwart O. A cluster of acute hepatitis C virus infection among men who
have sex with men - results from contact tracing and public health
implications. AIDS. 2005;19:969–9674.
2. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et
al. Sexually transmitted acute infection with a clustered genotype 4
hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral
therapy. AIDS. 2006;20:233–40.
3. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent
epidemic of acute hepatitis C virus in HIV-positive men who have sex with
men linked to high-risk sexual behaviours. AIDS. 2007;21:983–91.
4. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-
infected men who have sex with men: an emerging sexually transmitted
infection. AIDS. 2010;24:1799–812.
5. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA,
et al. Increase in HCV incidence among men who have sex with men in
Amsterdam most likely caused by sexual transmission. J Infect Dis.
2007;196:230–8.
6. Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A, et al.
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving
epidemic. Clin Infect Dis. 2012;55:1408–16.
7. Sánchez C, Plaza Z, Vispo E, de Mendoza C, Barreiro P, Fernández-Montero
JV, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-
infected men who have sex with men in Spain. Liver Int. 2013;33:1357–62.
8. Martínez-Rebollar M, Mallolas J, Pérez I, González-Cordón A, Loncà M,
Torres B, et al. Brote epidémico de hepatitis aguda C en pacientes
infectados por el virus de la inmunodeficiencia humana. Enferm Infecc
Microbiol Clin. 2015;33:3–8.
9. Montoya-Ferrer A, Fierer DS, Alvarez-Alvarez B, de Gorgolas M, Fernandez-
Guerrero ML. Acute hepatitis C outbreak among HIV-infected men, Madrid,
Spain. Emerg Infect Dis. 2011;17:1560–2.
10. Matthews GV, Pham ST, Hellard M, Grebely J, Zhang L, Oon A, et al. Patterns
and characteristics of hepatitis C transmission clusters among HIV-positive
and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin
Infect Dis. 2011;52:803–11.
11. Cifuentes C, Mancebo-Hernández M, Pérez-Navarro E, Recio E, Monje-Agudo
P, Valiente A, et al. Cambios en la prevalencia y distribución genotípica de
la coinfección por VHC en pacientes infectados por VIH. Enferm Infecc
Microbiol Clin. 2015;33:110–2.
12. Neukam K, García-Rey S, Cifuentes C, Macías J, Mira JA, Vázquez MJ, et al.
HIV-coinfection leads to a modest increase in plasma HCV-RNA load in
patients with chronic HCV infection. Antiviral Res. 2012;95:212–5.
13. Sobrino-Vegas P, Monge Corella S, Serrano-Villar S, Gutiérrez F, Blanco JR,
Santos I, et al. Incidence of hepatitis C virus (HCV) in a multicenter cohort of
HIV-positive patients in Spain 2004–2011: increasing rates of HCV diagnosis
but not of HCV seroconversions. PLoS One. 2014;9:e116226.
14. Rivero-Juarez A, Gutierrez-Valencia A, Castaño M, Merino D, Neukam K, Ríos-
Villegas MJ, et al. Dimension of chronic hepatitis C virus in HIV-infected
patients in the interferon-free era: an overview from south Spain. Eur J Clin
Microbiol Infect Dis. 2015;34:2247–55.
15. Mina MM, Luciani F, Cameron B, Bull RA, Beard MR, Booth D, Lloyd AR.
Resistance to hepatitis C virus: potential genetic and immunological
determinants. Lancet Infect Dis. 2015;15:451–60.
16. Gayán J, Galan JJ, González-Pérez A, Sáez ME, Martínez-Larrad MT,
Zabena C, et al. Genetic structure of the Spanish population. BMC
Genomics. 2010;11:326.
17. Kouyos RD, Rauch A, Böni J, Yerly S, Shah C, Aubert V, et al. Clustering of
HCV coinfections on HIV phylogeny indicates domestic and sexual
transmission of HCV. Int J Epidemiol. 2014;43:887–96.
18. Vogel M, van de Laar T, Kupfer B, Stellbrink HJ, Kümmerle T, Mauss S, et al.
Phylogenetic analysis of acute hepatitis C virus genotype 4 infections
among human immunodeficiency virus-positive men who have sex with
men in Germany. Liver Int. 2010;30:1169–72.
19. Vanhommering J, Lambers F, Prins M, Schinkel J, van der Meer J, Arends J,
et al. Risk factors for transmission of HCV among HIV-infected MSM: A case-
control study [abstract 674]. In: Program and Abstracts of the 22nd
Conference on Retroviruses and Opportunistic Infections (Seattle). Boston:
Infectious Diseases Society of America; 2015.
20. Schmidt AJ, Rockstroh JK, Vogel M, An der Heiden M, Baillot A, Krznaric
I, Radun D. Trouble with bleeding: risk factors for acute hepatitis C
among HIV-positive gay men from Germany–a case-control study.
PLoS One. 2011;6:e17781.
21. Kouyos RD, Rauch A, Braun DL, Yang WL, Böni J, Yerly S, et al. Higher risk of
incident hepatitis C virus coinfection among men who have sex with men,
in whom the HIV genetic bottleneck at transmission was wide. J Infect Dis.
2014;210:1555–61.
22. Macías J, Bernal S, Pareja M, Sánchez-Berná MA, Palomares JC, Robles A, et
al. Diversity of high-risk oncogenic human papillomavirus anal infection in
HIV-infected homosexual men (HM): Potential impact for the prevention of
anal dysplasia [abstract PE12.3/3]. In: Program and Abstracts of the 13th
European AIDS Conference/EACS (Belgrade) 2011. Brussels (Belgium):
European AIDS Clinical Society.
23. Pineda JA, Núñez-Torres R, Téllez F, Mancebo M, García F, Merchante N, et
al. Hepatitis C virus reinfection after sustained virological response in HIV-
infected patients with chronic hepatitis C. J Inf. 2015;71:571–7.
24. Boesecke C, Rockstroh JK. Acute hepatitis C in patients with HIV. Semin
Liver Dis. 2012;32:130–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Neukam et al. BMC Infectious Diseases  (2016) 16:489 Page 6 of 6
